-
EP1200580
European procedure
Extract from the Register of European Patents
EP About this file: EP1200580
| EP1200580 - MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 11.11.2005 Database last updated on 29.06.2024 | Most recent event Tooltip | 25.05.2007 | Change - lapse in a contracting state Updated state(s): LU | published on 27.06.2007 [2007/26] | Applicant(s) | For all designated states HYBRIDON, INC. 345 Vassar Street Cambridge Massachusetts 02139 / US | [N/P] |
| Former [2002/18] | For all designated states HYBRIDON, INC. 345 Vassar Street Cambridge, Massachusetts 02139 / US | Inventor(s) | 01 /
AGRAWAL, Sudhir 61 Lamplighter Drive Shrewsbury, MA 01545 / US | [2002/18] | Representative(s) | Grund, Martin, et al Dr. Volker Vossius Patentanwaltskanzlei Geibelstrasse 6 81679 München / DE | [N/P] |
| Former [2002/18] | Grund, Martin, Dr., et al Dr. Volker Vossius, Patentanwaltskanzlei, Holbeinstrasse 5 81679 München / DE | Application number, filing date | 00955527.7 | 14.08.2000 | [2002/18] | WO2000US22284 | Priority number, date | US19990148798P | 13.08.1999 Original published format: US 148798 P | [2002/18] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO0112804 | Date: | 22.02.2001 | Language: | EN | [2001/08] | Type: | A2 Application without search report | No.: | EP1200580 | Date: | 02.05.2002 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.02.2001 takes the place of the publication of the European patent application. | [2002/18] | Type: | B1 Patent specification | No.: | EP1200580 | Date: | 05.01.2005 | Language: | EN | [2005/01] | Search report(s) | International search report - published on: | EP | 07.09.2001 | Classification | IPC: | C12N15/11, C07H21/00, A61K31/7125, // A61P37:04 | [2002/18] | CPC: |
A61K31/7115 (EP,US);
C12N15/117 (EP,KR,US);
A61K31/711 (EP,US);
A61K31/712 (EP,US);
A61K31/7125 (EP,US);
A61P31/18 (EP);
A61P37/02 (EP);
A61P37/04 (EP);
A61P37/06 (EP);
A61K2039/55561 (EP,US);
C12N2310/18 (EP,US);
C12N2310/315 (EP,US);
| C-Set: |
C12N2310/321, C12N2310/3125 (US,EP);
C12N2310/321, C12N2310/3521 (EP,US) | Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2002/18] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | Not yet paid | SI | Not yet paid | Title | German: | MODULIERUNG DER DURCH CPG-OLIGONUKLEOTIDE VERURSACHTEN IMMUNSTIMULIERUNG DURCH POSITIONSBEDINGTE VERÄNDERUNG VON NUKLEOSIDEN | [2004/34] | English: | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES | [2002/18] | French: | MODULATION DE LA STIMULATION IMMUNITAIRE INDUITE PAR LES OLIGONUCLEOTIDES CPG PAR MODIFICATION DE LA POSITION DES NUCLEOSIDES | [2002/18] |
| Former [2002/18] | MODULIERUNG DER DURCH CPG-OLIGONUKLEOTIDE VERURSACHTE IMMUNSTIMULIERUNG DURCH POSITIONSBEDINGTE VERÄNDERUNG VON NUKLEOSIDEN | Entry into regional phase | 08.02.2002 | National basic fee paid | 08.02.2002 | Designation fee(s) paid | 08.02.2002 | Examination fee paid | Examination procedure | 13.03.2001 | Request for preliminary examination filed International Preliminary Examining Authority: US | 05.02.2002 | Amendment by applicant (claims and/or description) | 08.02.2002 | Examination requested [2002/18] | 25.07.2002 | Despatch of a communication from the examining division (Time limit: M04) | 28.11.2002 | Reply to a communication from the examining division | 20.12.2002 | Despatch of a communication from the examining division (Time limit: M04) | 30.04.2003 | Reply to a communication from the examining division | 27.05.2003 | Despatch of a communication from the examining division (Time limit: M04) | 25.09.2003 | Reply to a communication from the examining division | 03.11.2003 | Despatch of a communication from the examining division (Time limit: M04) | 03.03.2004 | Reply to a communication from the examining division | 23.07.2004 | Communication of intention to grant the patent | 26.10.2004 | Fee for grant paid | 26.10.2004 | Fee for publishing/printing paid | Divisional application(s) | EP04023362.9 / EP1496121 | EP10010051.0 / EP2314693 | Opposition(s) | 06.10.2005 | No opposition filed within time limit [2005/52] | Fees paid | Renewal fee | 22.08.2002 | Renewal fee patent year 03 | 25.08.2003 | Renewal fee patent year 04 | 23.08.2004 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | CY | 14.08.2005 | LU | 14.08.2005 | MC | 31.08.2005 | [2007/26] |
| Former [2007/20] | CY | 14.08.2005 | |
| LU | 31.08.2005 | ||
| MC | 31.08.2005 | ||
| Former [2007/08] | LU | 31.08.2005 | |
| MC | 31.08.2005 | ||
| Former [2006/28] | MC | 31.08.2005 | Cited in | International search | [DY]WO9706253 (HYBRIDON INC [US]) [DY] 1-23 * figures 2,3; example - *; | [A]WO9811211 (HYBRIDON INC [US]) [A] 1-15 * abstract * * page 11, line 17 - line 32 * * page 13, line 21 - page 14, line 10 *; | [XY]WO9818810 (UNIV IOWA RES FOUND [US], et al) [X] 16-23 * page 18 - page 22 * * page 63, line 10 - page 66, line 25 * [Y] 16-23; | [XY] - AGRAWAL S, "Mixed backbone oligonucleotides: Improvement in oligonucleotide-induced toxicity in vivo", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, (APR 1998) VOL. 8, NO. 2, PP. 135-139., XP002159337 [X] 1-3,6-10,13 * page 138, column L, line 31 - column R, line L * [Y] 1-15 | [X] - AGRAWAL S ET AL, "Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, (199712), vol. 7, no. 6, ISSN 1087-2906, pages 575 - 584, XP002122934 [X] 6-10,18-21 * figure 1 * * page 583, paragraph L * | [DXA] - ZHAO Q ET AL, "EFFECT OF DIFFERENT CHEMICALLY MODIFIED OLIGODEOXYNUCLEOTIDES ON IMMUNE STIMULATION", BIOCHEMICAL PHARMACOLOGY, (19960126), vol. 51, no. 2, ISSN 0006-2952, pages 173 - 182, XP000610208 [DX] 18,20,21 * the whole document * [A] 1-23 DOI: http://dx.doi.org/10.1016/0006-2952(95)02177-9 | [A] - H DAVIS ET AL, "CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen", JOURNAL OF IMMUNOLOGY, (19980115), vol. 160, no. 2, ISSN 0022-1767, pages 870 - 876, XP002109526 [A] 16-23 * page 871, column L, line 1 - line 10 * | [A] - KLINMAN D M, "Therapeutic applications of CpG -containing oligodeoxynucleotides", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, (1998), vol. 8, ISSN 1087-2906, pages 181 - 184, XP002128519 | [PX] - ZHAO Q ET AL, "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (19991220), vol. 9, no. 24, ISSN 0960-894X, pages 3453 - 3458, XP004185533 [PX] 1-23 * the whole document * DOI: http://dx.doi.org/10.1016/S0960-894X(99)00635-6 | [PX] - ZHAO Q ET AL, "Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (200005), vol. 10, no. 10, ISSN 0960-894X, pages 1051 - 1054, XP004204603 [PX] 1-23 * the whole document * DOI: http://dx.doi.org/10.1016/S0960-894X(00)00157-8 |